Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in

Authors

• Rossella Elisei
• Lori J Wirth
• Jaume Capdevila
• Ana Oliveira Hoff
• Makoto Tahara
• Eric J Sherman
• Mimi I Hu
• Ming-Hua Ge
• Jonathan Wadsley
• Fernanda Vaisman
• Katerina Kopeckova
• Jolanta Krajewska
• Dinorath Olvera
• Collin Churchill
• Patricia Maeda
• Adrienne M Gilligan
• Yan Lin
• Nalin Payakachat
• Bruce Robinson
• Julien Hadoux
• Marcia S Brose

Publication/Presentation Date

10-1-2025

Volume

35

Issue

10

First Page

1162

Last Page

1172

ISSN

1557-9077

Published In/Presented At

Elisei, R., Wirth, L. J., Capdevila, J., Hoff, A. O., Tahara, M., Sherman, E. J., Hu, M. I., Ge, M. H., Wadsley, J., Vaisman, F., Kopeckova, K., Krajewska, J., Olvera, D., Churchill, C., Maeda, P., Gilligan, A. M., Lin, Y., Payakachat, N., Robinson, B., Hadoux, J., … Brose, M. S. (2025). Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer. Thyroid : official journal of the American Thyroid Association, 35(10), 1162–1172. https://doi.org/10.1177/10507256251367352

Disciplines

Medicine and Health Sciences

PubMedID

40828665

Department(s)

Hematology-Medical Oncology Division

Document Type

Article